Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) generates news flow centered on its development of Antibody Oligonucleotide Conjugates (AOCs™), a class of RNA therapeutics designed to combine monoclonal antibody specificity with oligonucleotide precision. Company announcements frequently highlight progress across its late-stage neuromuscular pipeline, including programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
News items for RNA often cover clinical trial milestones, such as topline and long-term data from the EXPLORE44® and EXPLORE44-OLE™ studies of delpacibart zotadirsen (del-zota) in DMD44, enrollment and data plans for the HARBOR™ Phase 3 trial of del-desiran in DM1, and development updates for del-brax and the FORTITUDE™ and FORTITUDE-3™ programs in FSHD. Regulatory developments are another key theme, including the FDA’s Breakthrough Therapy designation for del-zota and disclosures about planned Biologics License Application (BLA) submissions.
Investors following Avidity’s news can also expect coverage of financing activities, such as public offerings of common stock, collaboration milestones with partners like Eli Lilly and Company and Bristol Myers Squibb, and updates on the company’s cash position as reported in periodic financial results. Corporate and strategic news includes participation in scientific and investor conferences, as well as detailed announcements about the definitive merger agreement with Novartis AG and the planned separation of early-stage precision cardiology programs into a new company referred to as SpinCo.
In addition, Avidity regularly reports on its engagement with patient and advocacy communities, particularly during National Muscular Dystrophy Awareness Month and events focused on Duchenne muscular dystrophy, myotonic dystrophy, FSHD and rare diseases. For readers tracking RNA, this news page provides a centralized view of clinical, regulatory, financial and transaction-related developments that shape the company’s trajectory.
Avidity Biosciences (RNA) has provided an update on its AOC 1001 treatment for myotonic dystrophy type 1 (DM1) from the Phase 1/2 MARINA trial. The FDA continues discussions regarding a partial clinical hold initiated in September 2022 due to a serious adverse event in a single participant. Avidity has found no biological link between the event and AOC 1001. Preliminary results show successful RNA delivery and early signs of clinical activity. A top-line safety data presentation is scheduled for the AAN Annual Meeting on April 27, 2023. Further dosing will occur in the ongoing MARINA-OLE extension study, with expectations for 2023 data release.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the granting of non-qualified stock options for 73,700 shares and 36,850 restricted stock units (RSUs) to six new non-executive employees on March 20, 2023. This is part of the company's 2022 Employment Inducement Incentive Award Plan, aimed at attracting talent following Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $20.07 per share, equal to the closing price on the grant date, and will vest over four years. Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs™) to target diseases previously untreatable by RNA therapeutics.
Avidity Biosciences (Nasdaq: RNA) announced its participation in the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, from March 19-22, 2023. The company will present two oral presentations on March 22, focusing on AOC 1020 for FSHD and the MARINA™ Trial for Myotonic Dystrophy Type 1. Additionally, Avidity will showcase multiple poster presentations covering various topics including healthcare utilization in Myotonic Dystrophy and innovative therapies for Duchenne Muscular Dystrophy. Presentations will be available on Avidity's website after the event.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the Cowen 43rd Annual Healthcare Conference on March 7 at 8:10 a.m. PT / 11:10 a.m. ET. A live webcast will be available on the 'Events and Presentations' page of Avidity's website, providing up-to-date details and an archived replay. Avidity is focused on developing a new class of RNA therapeutics, known as Antibody Oligonucleotide Conjugates (AOCs™), and currently has three programs in clinical development targeting various muscular dystrophies. The company aims to address previously untreatable diseases through its innovative therapies.
Avidity Biosciences, Inc. (RNA) announced its fourth quarter and full-year 2022 financial results, reporting cash and cash equivalents of $610.7 million. The company advanced three rare disease programs and successfully delivered RNA to muscle for the first time.
Collaboration revenue increased from $1.9 million in Q4 2021 to $2.7 million in Q4 2022. However, R&D expenses surged by 38% year-over-year, totaling $150.4 million for 2022, reflecting its ongoing clinical trials. General and Administrative expenses also grew significantly.
Looking forward, Avidity expects important data releases from its clinical trials in 2023, bolstering its pipeline and platform development.
Summary not available.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced the expansion of its internal pipeline with new research programs targeting skeletal muscle and cardiology. The company is advancing three Phase 1/2 clinical programs for rare diseases: AOC 1001 (myotonic dystrophy type 1), AOC 1020 (facioscapulohumeral muscular dystrophy), and AOC 1044 (Duchenne muscular dystrophy). Avidity's proprietary AOC platform combines monoclonal antibodies and oligonucleotide therapies, aiming to address previously untreatable conditions. Collaborations with Eli Lilly and MyoKardia further enhance this initiative, although Avidity has decided not to pursue projects in muscle atrophy and Pompe disease.
Avidity Biosciences, Inc. (Nasdaq: RNA) has made significant leadership changes as part of its strategy to enhance its RNA therapeutic development. Dr. Arthur A. Levin transitions from Chief Scientific Officer to a member of the board of directors while continuing his role as a distinguished scientist. Dr. W. Michael Flanagan has been promoted to Chief Scientific and Technical Officer, emphasizing his crucial technical expertise. This leadership adjustment aims to strengthen Avidity's mission of advancing Antibody Oligonucleotide Conjugates (AOCs) and expanding its clinical programs, including ongoing trials for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Avidity Biosciences, Inc. (NASDAQ: RNA) announced on February 20, 2023, that its Compensation Committee granted stock options and restricted stock units (RSUs) to three new non-executive employees. The total awards comprise 27,400 stock options and 13,700 RSUs as part of the 2022 Employment Inducement Incentive Award Plan, aimed at attracting new talent. The options have an exercise price of $25.65 per share, equating to Avidity's closing stock price on February 17, 2023. The stock options will vest over four years, while the RSUs will vest in four equal installments on the anniversaries of the grant date, dependent on ongoing employment.
Avidity Biosciences (Nasdaq: RNA) has announced that the FDA granted Orphan Drug designation to AOC 1020 for treating facioscapulohumeral muscular dystrophy (FSHD), a severe genetic disorder causing progressive muscle weakness. This designation aims to facilitate the development of treatments for rare diseases affecting fewer than 200,000 people in the U.S. AOC 1020 is currently in the Phase 1/2 FORTITUDE clinical trial, with preliminary data expected in mid-2024. The drug targets the DUX4 gene, the root cause of FSHD, and offers market exclusivity, fee exemption, and tax credits for clinical trials upon regulatory approval.